ANI Pharmaceuticals, Inc. (ANIP)
Company Info
US00182C1036
00182C103
May 5, 2000
Highlights
$1.43B
-$1.04
1.06
$476.95M
$261.20M
$25.16M
$52.50 - $77.00
$81.88
13.74%
5.71
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
ANI Pharmaceuticals, Inc. (ANIP) returned 19.93% year-to-date (YTD) and -2.57% over the past 12 months. Over the past 10 years, ANIP returned 2.60% annually, underperforming the S&P 500 benchmark at 10.46%.
ANIP
19.93%
1.81%
7.91%
-2.57%
13.81%
2.60%
^GSPC (Benchmark)
-3.77%
7.44%
-5.60%
8.37%
14.12%
10.46%
Monthly Returns
The table below presents the monthly returns of ANIP, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 6.08% | 5.54% | 8.18% | 5.78% | -6.38% | 19.93% | |||||||
| 2024 | 1.23% | 21.23% | 2.16% | -4.53% | -1.67% | -1.88% | 3.20% | -3.00% | -6.42% | -4.05% | -0.03% | -3.41% | 0.25% |
| 2023 | 11.19% | -6.46% | -5.07% | -5.04% | 19.67% | 19.25% | -2.38% | 22.53% | -9.83% | 6.34% | -19.32% | 10.70% | 37.06% |
| 2022 | -12.28% | -7.35% | -24.94% | 4.98% | 2.51% | -1.92% | 15.44% | 7.71% | -12.88% | 20.07% | 8.71% | -4.10% | -12.70% |
| 2021 | -1.72% | 1.96% | 24.19% | -7.91% | 3.22% | 2.04% | -3.20% | -10.61% | 8.21% | 13.89% | 10.06% | 12.01% | 58.68% |
| 2020 | 0.54% | -22.56% | -15.14% | -1.79% | -22.37% | 4.12% | -8.44% | 5.91% | -10.04% | -9.64% | 15.97% | -1.76% | -52.91% |
| 2019 | 19.37% | 22.42% | 7.22% | 0.62% | -1.86% | 18.00% | 2.91% | -22.57% | 11.27% | 7.18% | -21.11% | 0.08% | 36.98% |
| 2018 | 4.20% | -4.60% | -9.13% | 1.94% | 6.64% | 5.55% | 0.22% | -13.07% | -2.85% | -14.17% | 14.55% | -19.01% | -30.15% |
| 2017 | -0.28% | -2.28% | -16.18% | 9.31% | -19.27% | 7.12% | 4.12% | -1.50% | 9.35% | 10.65% | 22.43% | -9.37% | 6.32% |
| 2016 | -29.06% | 3.28% | 1.81% | 35.09% | 19.09% | 3.08% | 8.56% | -1.42% | 11.06% | -10.02% | -1.29% | 2.87% | 34.34% |
| 2015 | -0.74% | 20.35% | -7.14% | -2.51% | -17.38% | 23.16% | 14.47% | -31.34% | -18.99% | 5.90% | 4.73% | 2.98% | -19.98% |
| 2014 | 10.46% | 36.52% | 3.53% | -0.77% | 2.38% | 8.13% | -25.61% | 14.48% | -3.58% | 20.08% | 59.33% | 4.21% | 180.83% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of ANIP is 48, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for ANI Pharmaceuticals, Inc. (ANIP) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the ANI Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ANI Pharmaceuticals, Inc. was 98.57%, occurring on Jun 25, 2013. The portfolio has not yet recovered.
The current ANI Pharmaceuticals, Inc. drawdown is 82.36%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.57% | Nov 30, 2004 | 2157 | Jun 25, 2013 | — | — | — |
| -80.53% | Aug 21, 2001 | 320 | Apr 1, 2003 | 348 | Sep 21, 2004 | 668 |
| -21.69% | Jul 25, 2001 | 6 | Aug 1, 2001 | 11 | Aug 17, 2001 | 17 |
| -14.12% | Oct 8, 2004 | 20 | Nov 4, 2004 | 15 | Nov 26, 2004 | 35 |
| -10.82% | Sep 23, 2004 | 3 | Sep 27, 2004 | 6 | Oct 5, 2004 | 9 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ANI Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of ANI Pharmaceuticals, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -287.5%.
Valuation
The Valuation section provides an overview of how ANI Pharmaceuticals, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for ANIP compared to other companies in the Drug Manufacturers - Specialty & Generic industry. ANIP currently has a PEG ratio of 1.1. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ANIP relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ANIP has a P/S ratio of 2.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ANIP in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ANIP has a P/B value of 3.8. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |